Clinical trial · no report yet · Phase 1
NCT04277637
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
- NCT04277637 ↗
- Active not recruiting
- BeOne Medicines
- 7 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
- Phase
- Phase 1
- Status
- Active not recruiting
- Conditions
- Mature B-Cell Malignancies
- Interventions
- Sonrotoclax; Zanubrutinib; Obinutuzumab
- Arms
- Sonrotoclax Monotherapy Dose Finding: Part 1 · Experimental
- Sonrotoclax Monotherapy Expansion Cohorts: Part 2 · Experimental
- Sonrotoclax + Zanubrutinib Combination Therapy Dose Finding: Part 3 · Experimental
- Sonrotoclax + Zanubrutinib Combination Therapy Dose Expansion: Part 4 · Experimental
- Sonrotoclax + Zanubrutinib Combination Therapy Dose Escalation: Part 5 · Experimental
- Sonrotoclax + Zanubrutinib Combination Therapy Dose Expansion: Part 6 · Experimental
- Enrollment
- 437
- Primary outcomes
- Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
- Number of Participants Experiencing Serious Adverse Events (SAEs)
- Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax
- Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax
- Part 1, Part 3, Part 5: RP2D of Sonrotoclax
- Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events
- Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs
- Sponsor
- BeOne Medicines
- Start
- Mar 24, 2020
- Primary completion
- May 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04277637 · updated Jun 22, 2026